Assembly Biosciences, Inc. is a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biotherapeutics for disorders associated with the microbiome.


See all news


November 9, 2016
Assembly Updated Corporate Presentation
September 21, 2016
2016 International HBV Meeting, Seoul, South Korea, "Complete Blockage of HBV Virus Replication and Inhibition of cccDNA Formation by Core Protein Allosteric Modifiers"